Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276704 · ClinicalTrials.gov registry record · Phase 2
Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
A Phase 2 study, sponsored by Carol Fabian, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT01276704 is a Phase 2 study that was terminated before completion, run by Carol Fabian, MD. The registered enrollment target is 180 participants.
The verdict
NCT01276704, a Phase 2 study, was terminated before completion, sponsored by Carol Fabian, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.
Interventions
- DRUG Placebo
- DRUG secoisolariciresinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2011-01 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276704
The ClinicalTrials.gov registry entry for NCT01276704 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carol Fabian, MD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01276704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276704 about?
NCT01276704 is a clinical study titled "Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer". The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.
What is the current status of trial NCT01276704?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2011-01. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01276704?
The interventions under investigation include: Placebo (DRUG), secoisolariciresinol (DRUG).
Who is sponsoring clinical trial NCT01276704?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.